Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CASC10 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Injection
01
Overview
CASC10 siRNA is an experimental research compound designed to target and knock down the long noncoding RNA (lncRNA) CASC10 (cancer susceptibility candidate 10). CASC10 is significantly upregulated in cisplatin-resistant high-grade serous ovarian cancer (HGSOC) and is associated with poor prognosis. The drug utilizes small interfering RNA (siRNA) technology to reduce CASC10 expression, which in preclinical models has been shown to inhibit cell proliferation, invasion, and tumor growth while sensitizing cells to cisplatin treatment. In vivo studies have utilized liposomal delivery systems to administer the siRNA. Currently, CASC10 siRNA is primarily used as a research tool in academic settings and has not entered formal clinical development by a pharmaceutical sponsor.
- Other names
- liposomal CASC10 siRNA
02
Targets
CASC10 (Cancer susceptibility 10)
Beyond the preview
Go deeper on CASC10 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CASC10 siRNA.